Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
Actuate獲得FDA對Elraglusib用於治療軟組織肉瘤的孤兒藥物認定。
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
Actuate獲得FDA對Elraglusib用於治療軟組織肉瘤的孤兒藥物認定。
譯文內容由第三人軟體翻譯。